Metronomic therapy: Chemotherapy revisited.
Indian J Cancer
;
2013 Apr-June; 50(2): 142-148
Article
in English
| IMSEAR
| ID: sea-148639
ABSTRACT
Cytotoxic antiproliferative chemotherapeutic agents are the mainstay of treatment in cancers. Chemotherapy is usually administered every 2–3 weeks. Along with acute toxicity and long‑term effects of cumulative doses, this strategy potentially allows regrowth of the tumor in the interval period and leads to the emergence of resistant populations of tumor cells. Moreover, even with intense chemotherapy, the outcome is stagnating for most of the tumors. There has been recent interest in the use of chemotherapy in fractionated doses which is far below the maximum tolerated dose. This is called metronomic scheduling of chemotherapy. Here, we review the biology and evidence for metronomic chemotherapy.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Antineoplastic Combined Chemotherapy Protocols
/
Angiogenesis Inhibitors
/
Administration, Metronomic
/
Neoplasms
/
Neovascularization, Pathologic
Language:
English
Journal:
Indian J Cancer
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS